Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PyramIDH study of ivosidenib versus azacitidine monotherapy in HMA-naive IDH1-mutated myelodysplastic syndrome
NL-OMON58725Phase 3Recruiting
- Sponsor
- Servier
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Ivosidenib monotherapy with Azacitidine monotherapy (2 arms). Primary endpoint: Complete remission plus partial remission by 4 months. Started Aug 2025; status: recruiting.
02
Drugs
ivosidenibazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON58725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58725.